ArticleFrontiers in aging2025
Circulatory titin and miR-451a are possible sarcopenia biomarkers in elderly people.
Article in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Biomarkers of Inflammaging and Cellular Senescence in Musculoskeletal (MSK) Diseases: The Knowns and the Unknowns.Biomedicines · 2026Article
- Emerging roles of epigenetics in the pathogenesis of sarcopenia.Epigenomics · 2026Review
- Risk Factors, Diagnostic Challenges, and Emerging Therapeutic Strategies for ICU-Acquired Weakness: A Brief Review.Journal of multidisciplinary healthcare · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sarcopenia is a clinical syndrome characterized by decline of muscle mass, strength or physical performance that occur with advancing age. Diagnosis is currently based on assessment of muscle mass and performance. New biomarkers are needed in clinical practice for diagnosis, monitoring and treatment of sarcopenia. The measurement in urine of titin (TTN), a muscular protein essential for structure and function of sarcomere, has been recently suggested as useful biomarker for the diagnosis of sarcopenia. The titin N-terminal fragment (N-TTN), produced by proteolysis during muscle damage, is released in the bloodstream and is secreted in the urine, and it was suggested as indicator of muscle injury. The primary aim of our study is to evaluate the potential of serum TTN and N-TTN expression as biomarker of sarcopenia, an aspect that has not been the subject of much research so far. Additionally, the secondary aim is to explore possible relationship between the serum expression of titin and miR-451a, its possible miRNA regulator. Methods: We verified serum TTN, N-TTN and miR-451a concentration in a cohort of 70 sarcopenic patients who were undergoing rehabilitation; results were compared to those obtained in 90 age- and sex-matched healthy controls (HC). Results: Results showed that TTN and N-terminal TTN (N-TTN) (p < 0.0005 for both) and miR-451a (p < 0.0001) were significantly upregulated in serum of patients compared to HC. Rehabilitation significantly reduced TTN and N-TTN expression (p < 0.05 for all), while induced a significant increase in miR-451a expression (p = 0.008); ROC analysis showed that the change of miR-451a may be a predictive biomarker for rehabilitation outcome (p = 0.0198). Discussion: This study suggests the involvement of TTN, N-TTN and miR-451a in sarcopenia; moreover, the monitoring of miR-451a concentration may be useful proxy to measure the effectiveness of rehabilitation intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.